文献速递老年慢病共病管理多重用药

养老院居民心衰住院前后糖尿病药物使用情况

Use of Diabetes Medications before and after a Heart Failure-Related Hospitalization among Nursing Home Residents.
PubMed 文献 · J Am Med Dir Assoc · 2023-08-05

该队列研究基于20% Medicare索赔与Minimum Data Set评估链接数据,纳入12,990例长期居住养老院且合并2型糖尿病、在2013年1月1日至2018年8月31日间发生心衰相关住院的居民。结果显示,住院前使用SGLT-2i和GLP-1RA的比例极低(分别为0.3%和1.2%),而TZD和SU仍有使用(分别为1.5%和14.1%);出院后TZD和SU继续使用比例较高,且部分为新使用者。结论提示养老院心衰住院糖尿病患者中新类降糖药使用不足,TZD和SU仍被较多使用。

要点

  • 养老院心衰住院的2型糖尿病患者中,SGLT-2i和GLP-1RA使用率极低。
  • 心衰住院后TZD和SU仍被较多居民使用,TZD新用户占37%,SU新用户占10%。
  • 提示存在阻碍新类降糖药用于预防心衰的障碍,需进一步研究。

核心结论

  • 在养老院合并2型糖尿病且发生心衰相关住院的居民中,GLP-1RA和SGLT-2i很少使用,而TZD和SU在住院后仍被许多居民使用。

研究设计与样本

  • 本研究为队列研究,使用20% Medicare索赔数据与Minimum Data Set居民评估链接。
  • 研究对象为2013年1月1日至2018年8月31日间发生心衰相关住院的长期居住养老院且合并2型糖尿病的居民,共12,990例,平均年龄78岁,66%女性,19%黑人。
  • 对多次心衰住院者随机选择1次住院;通过Medicare Part D索赔确定出院前120天和出院后120天(或专业护理机构出院后)的糖尿病药物使用。

主要发现

  • 住院前使用TZD者占1.5%,SU者占14.1%,GLP-1RA者占1.2%,SGLT-2i者占0.3%。
  • 住院前使用TZD、SU、GLP-1RA和SGLT-2i者中,分别有49%、62%、60%和40%继续使用。
  • 住院后使用TZD、SU、GLP-1RA和SGLT-2i者中,分别有37%、10%、28%和11%为新使用者。

临床怎么用

  • 养老院医生应关注心衰住院后糖尿病药物的调整,尤其需评估TZD和SU的继续使用是否合理。
  • 对于合并心衰的2型糖尿病养老院居民,可考虑评估SGLT-2i和GLP-1RA的适用性,但需结合个体情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer cardiovascular benefits, whereas thiazolidinediones (TZDs) and sulfonylureas (SUs) increase cardiovascular risk. The objective of this study was to describe the use of SGLT-2is, GLP-1RAs, TZDs, and SUs before and after a heart failure (HF)-related hospitalization in nursing home (NH) residents with type 2 diabetes (T2D). DESIGN: This was a cohort study using a 20% sample of Medicare claims linked with Minimum Data Set resident assessments. SETTING AND PARTICIPANTS: The study population was long-stay NH residents with T2D and an HF-related hospitalization between January 1, 2013, and August 31, 2018. For individuals with multiple HF hospitalizations, 1 hospitalization was randomly selected. METHODS: We ascertained diabetes medications using Medicare Part D claims during the 120 days before and after hospital discharge (or skilled nursing facility discharge, where applicable). We calculated (1) the proportion of study participants who received a medication class of interest during pre- and posthospitalization periods; (2) the proportion of continuous users; and (3) the proportion of posthospitalization users who were new users. RESULTS: A total of 12,990 NH residents with T2D and an HF-related hospitalization were included (mean age 78 years, 66% female, 19% Black). Before hospitalization, 1.5% received TZDs, 14.1% received SUs, 1.2% received GLP-1RAs, and 0.3% received SGLT-2is. Among prehospitalization users of TZDs, SUs, GLP-1RAs, and SGLT-2is, 49%, 62%, 60%, and 40% continued the medications, respectively. Among posthospitalization users of TZDs, SUs, GLP-1RAs, and SGLT-2is, 37%, 10%, 28%, and 11%, respectively, were new users. CONCLUSIONS: Among NH residents with hospitalized HF, GLP-1RAs and SGLT-2is were seldom used. TZDs and SUs were still used by many residents with T2D after HF hospitalizations. IMPLEMENTATIONS: Barriers may exist in the use of newer diabetes medications to prevent heart failure in NH residents with T2D, which warrants further studies in older adults with multimorbidity.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Zhang T, Zullo AR, Hayes KKN, et al. Use of Diabetes Medications before and after a Heart Failure-Related Hospitalization among Nursing Home Residents. J Am Med Dir Assoc. 2023. PMID: 37553080. doi:10.1016/j.jamda.2023.06.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。